A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (NAVIGATOR)

drug protocol number

D5180C00007

drug sponsor

AstraZeneca

drug study

Tezepelumab

drug trial site

King Abdulaziz University Hospital (Jeddah), King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah)

drug status

Ongoing

drug phase